Clinical trials: Exacerbation Copd
Pulmonary Disease, Chronic Obstructive
A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444)) delivered once daily via a Novel…
- Trial name
- NCT01551758
- Testing
- FF/VI, Existing Maintenance Therapy
- Where
- 178 sites in United Kingdom
- Volunteers
- 2,802 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Effect of Blood Flow Restriction Resistance Exercises in COPDAE In-patient Rehabilitation
This is a randomised controlled trial of the blood flow restriction resistance exercise (BFR-RE) for early rehabilitation of chronic obstructive pulmonary disease acute exacerbation (COPDAE) in the Haven of Hope Hospital.
- Trial name
- NCT04448236
- Testing
- Blood flow restriction resistance exercise
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Hospital Authority, Hong Kong
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Bronchitis
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory…
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00181207
- Testing
- pneumatic vest
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
COPD Exacerbation Acute
Treatment of Pneumocystis in COPD (the TOPIC Study)
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated with chronic inflammation in the airways and lung, resulting in significant morbidity and mortality worldwide.
- Trial name
- NCT05418777
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
COPD Exacerbation
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics…
- Trial name
- NCT00789997
- Testing
- Prednisone, Etanercept, levofloxacin
- Volunteers
- 81 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Markers and Prognosis
The study aim is to verify the association between the changes in markers of disease and patient´s prognosis in chronic obstructive pulmonary disease.
- Trial name
- NCT00605540
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
COPD
A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab.
- Trial name
- SUMMER (NCT05138250)
- Testing
- Mepolizumab 100 MG
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Chronic Obstructive Pulmonary Disease
Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
Exacerbations of chronic obstructive pulmonary disease (COPD) are the first cause of admission to Pulmonary Department in Italy and worldwide.
- Trial name
- NCT01125098
- Testing
- PRO-CT values
- Where
- Italy
- Volunteers
- 183 people
- Sponsor
- University of Modena and Reggio Emilia
Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Some patients with chronic obstructive pulmonary diseases (COPD) have large number of specific white blood cells called eosinophils in their airways.
- Conditions
- Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation, Bronchitis
- Trial name
- NCT01463644
- Testing
- Mepolizumab
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- McMaster University
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Emphysema
Macrophage Phagocytosis in COPD
Patients with chronic obstructive pulmonary disease (COPD) that have frequent chest infections are the patients most likely to become worse over time. Why these people are more susceptible to chest infections is not known.
- Conditions
- Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis
- Trial name
- NCT00298389
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COPD Exacerbation
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized…
- Trial name
- NCT04655170
- Testing
- Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Graduate School of Medicine